

Ovarian Cancer (Epithelial) Pathways

Patient Name: _____ Date of Birth: _____

Member ID: _____ Treatment Start Date: _____

Stage: _____ Pathology: _____

ECOG Status: 1 2 3 4 ICD-10 Code: _____

Line of Therapy:

Neoadjuvant/Pre-op Adjuvant/Post Op 1st Line 2nd Line 3rd Line 3rd Line+ Maintenance

Biomarkers/Attributes: (select all that apply)

Platinum Sensitive*: <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not Reported	BRAC1 Status: <input type="checkbox"/> Germline Mutation <input type="checkbox"/> Wild Type (no mutation)
Platinum Resistant/Refractory*: <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not Reported	<input type="checkbox"/> Somatic Mutation <input type="checkbox"/> Not Reported
Paclitaxel Resistant: <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not Reported	BRAC2 Status: <input type="checkbox"/> Germline Mutation <input type="checkbox"/> Wild Type (no mutation)
NRTK Fusion: <input type="checkbox"/> Negative <input type="checkbox"/> Positive <input type="checkbox"/> Not Reported	<input type="checkbox"/> Somatic Mutation <input type="checkbox"/> Not Reported
HRD: <input type="checkbox"/> Negative <input type="checkbox"/> Positive <input type="checkbox"/> Not Reported	Microsatellite instability: <input type="checkbox"/> dMMR/ MSI-H <input type="checkbox"/> TMB-H (≥ 10 mut/Mb)
	<input type="checkbox"/> MSI-L <input type="checkbox"/> Not Reported

* Platinum sensitive is defined as recurrence of greater than 6 months after prior platinum-based therapy and resistance is defined as a recurrent of less than 6 months after prior platinum-based therapy

Neoadjuvant Therapy

Carboplatin + Paclitaxel[#]

Adjuvant or Primary Therapy

Carboplatin + Paclitaxel[#]

Carboplatin

Maintenance Therapy After Primary Therapy

Olaparib (germline/somatic BRCA mutation only)

Niraparib

Platinum-Sensitive Recurrent Disease - 1st + Subsequent Line of Therapy

Carboplatin + Gemcitabine

Carboplatin + Liposomal Doxorubicin

Carboplatin + Paclitaxel

Platinum-Sensitive Recurrent Disease - Maintenance Therapy

Olaparib

Niraparib

Platinum- Resistant Recurrent Disease - 1st + Subsequent Lines of Therapy

Gemcitabine

Liposomal Doxorubicin

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.



- Liposomal Doxorubicin + Bevacizumab**
- Paclitaxel (weekly)
- Paclitaxel (weekly) + Bevacizumab**
- Tamoxifen

Only intravenous carboplatin + paclitaxel are pathway regimens, peritoneal is not included.

**A biosimilar agent may be preferred under the patient's specific health plan

References:

Aghajanian, C., Blank, S.V., Goff, B.A., et al. OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer. *J Clin Oncol.* 2012;30(17):2039–2045. doi:10.1200/JCO.2012.42.0505

Alsop, K., Fereday, S., Meldrum, C., et al. BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group. *J Clin Oncol* 2012; 30: 2654–63

Alvarez Secord, A., Berchuck, A., Higgins, R.V., et al. A Multicenter, Randomized, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of Combination Docetaxel and Carboplatin and Sequential Therapy With Docetaxel Then Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer. *Cancer.* 2012;118(13):3283–3293. doi:10.1002/cncr.26610

Argenta, P.A., Thomas, S.G., Judson, P.L., et al. A Phase II Study of Fulvestrant in the Treatment of Multiply-Recurrent Epithelial Ovarian Cancer. *Gynecol Oncol.* 2009;113(2):205–209. doi:10.1016/j.ygyno.2009.01.012

Argenta, P.A., Thomas, S.G., Judson, P.L., et al. A Phase II Study of Fulvestrant in the Treatment of Multiply-Recurrent Epithelial Ovarian Cancer. *Gynecol Oncol.* 2009;113(2):205–209. doi:10.1016/j.ygyno.2009.01.012

Armstrong, D.K., Bundy, B., Wenzel, L., et al. Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer. *N Engl J Med.* 2006 Jan 5;354(1):34–43. PMID: 16394300

Bajetta, E., Di Leo, A., Biganzoli, L., et al. Phase II Study of Vinorelbine in Patients With Pretreated Advanced Ovarian Cancer: Activity in Platinum-Resistant Disease. *J Clin Oncol.* 1996;14(9):2546–2551. doi:10.1200/JCO.1996.14.9.2546

Bajetta, E., Di Leo, A., Biganzoli, L., et al. Phase II Study of Vinorelbine in Patients With Pretreated Advanced Ovarian Cancer: Activity in Platinum-Resistant Disease. *J Clin Oncol.* 1996;14(9):2546–2551. doi:10.1200/JCO.1996.14.9.2546

Banerjee S, Moore KN, Colombo N, et al: Maintenance olaparib for patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO-1. ESMO Virtual Congress 2020. Abstract 811MO. Presented September 18, 2020.

Barber, E.L., Zsiros, E., Lurain, J.R., et al. The Combination of Intravenous Bevacizumab and Metronomic Oral Cyclophosphamide Is an Effective Regimen for Platinum-Resistant Recurrent Ovarian Cancer. *J Gynecol Oncol.* 2013;24(3):258–264. doi:10.3802/jgo.2013.24.3.258

Bell, J., Brady, M.F., Young, R.C., et al. Randomized Phase III Trial of Three Versus Six Cycles of Adjuvant Carboplatin and Paclitaxel in Early Stage Epithelial Ovarian Carcinoma: A Gynecologic Oncology Group Study. *Gynecol Oncol.* 2006 Sep;102(3):432–9. Epub 2006 Jul 24

Benigno, B.B., Burrell, M.O., Daugherty, P., et al. (2016). A Phase II Nonrandomized Study of NabPaclitaxel Plus Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer. Retrieved from ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.5011

Bonaventura, A., O'Connell, R.L., Mapagu, C., et al. Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or Refractory Recurrent Ovarian Cancer. *Int J Gynecol Cancer.* 2017;27(5):900–906. doi:10.1097/IGC.0000000000000978

Bonaventura, A., O'Connell, R.L., Mapagu, C., et al. Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or Refractory Recurrent Ovarian Cancer. *Int J Gynecol Cancer.* 2017;27(5):900–906. doi:10.1097/IGC.0000000000000978

Bookman, M.A., Brady, M.F., McGuire, W.P., et al. Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer Intergroup. *J Clin Oncol.* 2009 Mar 20;27(9):1419–25. doi: 10.1200/JCO.2008.19.1684. Epub 2009 Feb 17

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Burger, R.A., Brady, M.F., Bookman, M.A., et al. Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. *N Engl J Med*. 2011 Dec 29;365(26):2473-83. doi: 10.1056/NEJMoa1104390

Burger, R.A., Brady, M.F., Rhee, J., Independent Radiologic Review of the Gynecologic Oncology Group Study 0218, a Phase III Trial of Bevacizumab in the Primary Treatment of Advanced Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer. *Gynecol Oncol*. 2013 Oct;131(1):21-6. doi: 10.1016/j.ygyno.2013.07.100. Epub 2013 Jul 29

Burger, R.A., Sill, M.W., Monk, B.J., et al. Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study [published correction appears in *J Clin Oncol*. 2014 Nov 10;32(32):3686]. *J Clin Oncol*. 2007;25(33):5165–5171. doi:10.1200/JCO.2007.11.5345

Burger, R.A., Sill, M.W., Monk, B.J., et al. Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study [published correction appears in *J Clin Oncol*. 2014 Nov 10;32(32):3686]. *J Clin Oncol*. 2007;25(33):5165–5171. doi:10.1200/JCO.2007.11.5345

Cannistra, S.A., Matulonis, U.A., Penson, R.T., et al. Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer [published correction appears in *J Clin Oncol*. 2008 Apr 1;26(10):1773]. *J Clin Oncol*. 2007;25(33):5180–5186. doi:10.1200/JCO.2007.12.0782

Chekerov, R., Hilpert, F., Mahner, S., et al. Sorafenib Plus Topotecan Versus Placebo Plus Topotecan for Platinum-Resistant Ovarian Cancer (TRIAS): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial. *Lancet Oncol*. 2018;19(9):1247–1258. doi:10.1016/S1470-2045(18)30372-3

Chollet, P., Bensmaïne, M.A., Brienza, S., et al. Single-Agent Activity Of Oxaliplatin in Heavily Pretreated Advanced Epithelial Ovarian Cancer. *Ann Oncol*. 1996;7(10):1065–1070. doi:10.1093/oxfordjournals.annonc.a010500

Clamp, A.R., James, E.C., McNeish, I.A., et al. Weekly Dose-Dense Chemotherapy in First-Line Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Treatment (ICON8): Primary Progression Free Survival Analysis Results From a GCIg Phase 3 Randomised Controlled Trial. *Lancet* 2019;394:2084-95

Coleman, R.L., Brady, M.F., Herzog, T.J., et al. Bevacizumab and Paclitaxel-Carboplatin Chemotherapy and Secondary Cytoreduction in Recurrent, Platinum-Sensitive Ovarian Cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): A Multicentre, Open-Label, Randomised, Phase 3 Trial. *Lancet Oncol*. 2017;18(6):779–791. doi:10.1016/S1470-2045(17)30279-6

Coleman, R.L., Brady, W.E., McMeekin, D.S., et al. A Phase II Evaluation of Nanoparticle, Albumin-Bound (Nab) Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study. *Gynecol Oncol*. 2011;122(1):111-115. doi:10.1016/j.ygyno.2011.03.036

Coleman, R.L., Oza, A.M., Lorusso, D., et al. Rucaparib Maintenance Treatment for Recurrent Ovarian Carcinoma After Response to Platinum Therapy (ARIEL3): A Randomised, Double-Blind, Placebo Controlled, Phase 3 Trial [published correction appears in *Lancet*. 2017 Oct 28;390(10106):1948]. *Lancet*. 2017;390(10106):1949–1961. doi:10.1016/S0140-6736(17)32440-6

Coleridge, S.L., Bryant, A., Lyons, T.J., et al. Chemotherapy Versus Surgery for Initial Treatment in Advanced Ovarian Epithelial Cancer. *Cochrane Database Syst Rev*. 2019;2019(10):CD005343. Published 2019 Oct 31. doi:10.1002/14651858.CD005343.pub4

Dal Molin, G.Z., Westin, S.N., Coleman, R.L. Rucaparib in Ovarian Cancer: Extending the Use of PARP Inhibitors in the Recurrent Disease. *Future Oncol*. 2018;14(30):3101-3110. doi:10.2217/fon-2018-0215

Dann, R.B., DeLoia, J.A., Timms, K.M., et al. BRCA1/2 Mutations and Expression: Response to Platinum Chemotherapy in Patients With Advanced Stage Epithelial Ovarian Cancer. *Gynecol Oncol* 2012; 125: 677–82

del Carmen, M.G., Fuller, A.F., Matulonis, U., et al. Phase II Trial of Anastrozole in Women With Asymptomatic Müllerian Cancer. *Gynecol Oncol*. 2003;91(3):596–602. doi:10.1016/j.ygyno.2003.08.021

del Carmen, M.G., Fuller, A.F., Matulonis, U., et al. Phase II Trial of Anastrozole in Women With Asymptomatic Müllerian Cancer. *Gynecol Oncol*. 2003;91(3):596–602. doi:10.1016/j.ygyno.2003.08.021

Diaz, L., Marabelle, A., et al. Efficacy of Pembrolizumab in Phase 2 KEYNOTE-164 and KEYNOTE-158 Studies of Microsatellite Instability High Cancers Presented at the European Society for Medical Oncology Congress; Madrid, Spain; 8-12 September 2017. Poster 386P

Domchek, S.M., Aghajanian, C., Shapira-Frommer, R., et al. Efficacy and Safety of Olaparib Monotherapy in Germline BRCA1/2 Mutation Carriers With Advanced Ovarian Cancer and Three or More Lines of Prior Therapy. *Gynecol Oncol*. 2016;140(2):199–203. doi:10.1016/j.ygyno.2015.12.020

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Dose Accompanied by Filgrastim at Two Dose Levels in Platinum-Pretreated Epithelial Ovarian Cancer: An Intergroup Study. *J Clin Oncol.* 2003;21(15):2843–2848. doi:10.1200/JCO.2003.10.082

Falandry C, Savoye AM, Stefani L, et al. EWOC-1: A randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): A GCIGENGOT-GINECO study. *J Clin Oncol.* 2019; 37: 5508-5508.

Falandry, C., Savoye, A.M., Stefani, L., et al. EWOC-1: A Randomized Trial to Evaluate the Feasibility of Three Different First-Line Chemotherapy Regimens for Vulnerable Elderly Women With Ovarian Cancer (OC): A GCIG-ENGOT-GINECO Study. *J Clin Oncol.* 2019; 37: 5508-5508

Falandry, C., Savoye, A.M., Stefani, L., et al. EWOC-1: A Randomized Trial to Evaluate the Feasibility of Three Different First-Line Chemotherapy Regimens for Vulnerable Elderly Women With Ovarian Cancer (OC): A GCIG-ENGOT-GINECO Study. *J Clin Oncol.* 2019; 37: 5508-5508

Ferrandina, G., Corrado, G., Mascilini, F., et al. Metronomic Oral Cyclophosphamide (MOC) in the Salvage Therapy of Heavily Treated Recurrent Ovarian Cancer Patients: A Retrospective, Multicenter Study. *BMC Cancer* 14, 947 (2014). Retrieved from doi.org/10.1186/1471-2407-14-947

Ferrandina, G., Corrado, G., Mascilini, F., et al. Metronomic Oral Cyclophosphamide (MOC) in the Salvage Therapy of Heavily Treated Recurrent Ovarian Cancer Patients: A Retrospective, Multicenter Study. *BMC Cancer* 14, 947 (2014). Retrieved from doi.org/10.1186/1471-2407-14-947

Ferrandina, G., Ludovisi, M., Lorusso, D., et al. Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian Cancer. *J Clin Oncol.* 2008;26(6):890-896. doi:10.1200/JCO.2007.13.6606

Fracasso, P.M., Blessing, J.A., Morgan, M.A., et al. Phase II Study of Oxaliplatin in Platinum-Resistant and Refractory Ovarian Cancer: A Gynecologic Group Study. *J Clin Oncol.* 2003;21(15):2856–2859. doi:10.1200/JCO.2003.03.077

Friedlander, M., Hancock, K.C., Rischin, D., et al. A Phase II, Open-Label Study Evaluating Pazopanib in Patients With Recurrent Ovarian Cancer. *Gynecol Oncol.* 2010;119(1):32–37. doi:10.1016/j.ygyno.2010.05.033

Friedlander, M., Hancock, K.C., Rischin, D., et al. A Phase II, Open-Label Study Evaluating Pazopanib in Patients With Recurrent Ovarian Cancer. *Gynecol Oncol.* 2010;119(1):32–37. doi:10.1016/j.ygyno.2010.05.033

Garcia, A.A., Hirte, H., Fleming, G., et al. Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago and Princess Margaret Hospital Phase II Consortia. *J Clin Oncol.* 2008;26(1):76-82. doi:10.1200/JCO.2007.12.1939 80.

Rose, P.G., Blessing J.A., Ball, H.G., et al. A Phase II Study of Docetaxel in Paclitaxel-Resistant Ovarian and Peritoneal Carcinoma: A Gynecologic Oncology Group Study. *Gynecol Oncol.* 2003;88(2):130-135. doi:10.1016/s0090-8258(02)00091-4

Gershenson, D.M., Miller, A., Brade, W., et al. (2019). LBA61A Randomized Phase II/III Study to Assess the Efficacy of Trametinib in Patients With Recurrent or Progressive Low-Grade Serous Ovarian or Peritoneal Cancer. Retrieved from researchgate.net/publication/336195140_LBA61A_randomized_phase_IIIII_study_to_assess_the_efficacy_

Gershenson, D.M., Miller, A., Brade, W., et al. (2019). LBA61A Randomized Phase II/III Study to Assess the Efficacy of Trametinib in Patients With Recurrent or Progressive Low-Grade Serous Ovarian or Peritoneal Cancer. Retrieved from researchgate.net/publication/336195140_LBA61A_randomized_phase_IIIII_study_to_assess_the_efficacy_of_trametinib_in_patients_with_recurrent_or_progressive_low-grade_serous_ovarian_or_peritoneal_cancer

Gonzalez-Martin, A., Pothuri, B., Vergote, I., et al. Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer. *NEJM.* 2019; 381: 2391-2402

Gordon, A.N., Fleagle, J.T., Guthrie, D., et al. Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan. *J Clin Oncol.* 2001;19(14):3312- 3322. doi:10.1200/JCO.2001.19.14.3312

Gynecologic Oncology Group, Markman, M., Blessing, J., et al. Phase II Trial of Weekly Paclitaxel (80 Mg/M²) in Platinum and Paclitaxel-Resistant Ovarian and Primary Peritoneal Cancers: A Gynecologic Oncology Group Study. *Gynecol Oncol.* 2006;101(3):436-440. doi:10.1016/j.ygyno.2005.10.036

Hardesty MM, Krivak T, Wright GS, et al: Phase 2 OVARIO study of niraparib plus bevacizumab therapy in advanced ovarian cancer following frontline platinum-base chemotherapy with bevacizumab. Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer. Poster 22. Presented March 19, 2021

Jin, W. Roles of TrkC Signaling in the Regulation of Tumorigenicity and Metastasis of Cancer. *Cancers* 2020, 12, 147

Jin, W. Roles of TrkC Signaling in the Regulation of Tumorigenicity and Metastasis of Cancer. *Cancers* 2020, 12, 147

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Katsumata, N., Yasuda, M., Isonishi, S., et al. Long-Term Results of Dose-Dense Paclitaxel and Carboplatin Versus Conventional Paclitaxel and Carboplatin for Treatment of Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (JGOG 3016): A Randomised, Controlled, Open-Label Trial. *Lancet Oncol.* 2013 Sep;14(10):1020-6. doi: 10.1016/S1470-2045(13)70363-2. Epub 2013 Aug 13

Kaufman, B., Shapira-Frommer, R., Schmutzler, R.K., et al. Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation. *J Clin Oncol.* 2015;33(3):244–250. doi:10.1200/JCO.2014.56.2728

Kaufman, B., Shapira-Frommer, R., Schmutzler, R.K., et al. Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation. *J Clin Oncol.* 2015;33(3):244–250. doi:10.1200/JCO.2014.56.2728

Kavanagh, J.J., Kudelka, A.P., de Leon, C.G., et al. Phase II Study of Docetaxel in Patients With Epithelial Ovarian Carcinoma Refractory to Platinum. *Clin Cancer Res.* 1996;2(5):837-842

Kristeleit R, Lisyanskaya A, Fedenko A, et al. Rucaparib versus chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious BRCA mutation: efficacy and safety from ARIEL4, a randomized phase 3 study. Presented at: Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer; March 19-25, 2021; Virtual. Abstract 11479.

Kushner, D.M., Connor, J.P., Sanchez, F., et al. Weekly Docetaxel and Carboplatin for Recurrent Ovarian and Peritoneal Cancer: A Phase II Trial. *Gynecol Oncol.* 2007;105(2):358–364. doi:10.1016/j.ygyno.2006.12.018

Le, D.T., Durham, J.N., Smith, K.N., et al. Mismatch Repair Deficiency Predicts Response of Solid Tumors to PD-1 Blockade. *Science.* 2017;357(6349):409–413. doi:10.1126/science.aan6733

Ledermann JA, Oza AM, Lorusso D, et al. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo controlled, phase 3 trial. *Lancet Oncol.* 2020 May;21(5):710-722. doi: 10.1016/S1470-2045(20)30061-9. PMID: 32359490.

Lindemann, K., Gibbs, E., Åvall-Lundqvist, E., et al. Chemotherapy vs. Tamoxifen in Platinum-Resistant Ovarian Cancer: A Phase III, Randomised, Multicentre Trial (Ovaresist). *Br J Cancer.* 2017;116(4):455–463. doi:10.1038/bjc.2016.435

Marinaccio, M., D’Addario, V., Serrati, A., et al. Leuprolide Acetate as a Salvage-Therapy in Relapsed Epithelial Ovarian Cancer. *Eur J Gynaecol Oncol.* 1996;17(4):286–288

Markman, M., Hakes, T., Reichman, B., et al. Ifosfamide and Mesna in Previously Treated Advanced Epithelial Ovarian Cancer: Activity in Platinum-Resistant Disease. *J Clin Oncol.* 1992;10(2):243–248. doi:10.1200/JCO.1992.10.2.243

Markman, M., Hakes, T., Reichman, B., et al. Ifosfamide and Mesna in Previously Treated Advanced Epithelial Ovarian Cancer: Activity in Platinum-Resistant Disease. *J Clin Oncol.* 1992;10(2):243–248. doi:10.1200/JCO.1992.10.2.243

Matsumoto, K., Katsumata, N., Yamanaka, Y., et al. The Safety and Efficacy of the Weekly Dosing of Irinotecan for Platinum- and Taxanes-Resistant Epithelial Ovarian Cancer. *Gynecol Oncol.* 2006;100(2):412–416. doi:10.1016/j.ygyno.2005.10.013

Matsumoto, K., Katsumata, N., Yamanaka, Y., et al. The Safety and Efficacy of the Weekly Dosing of Irinotecan for Platinum- and Taxanes-Resistant Epithelial Ovarian Cancer. *Gynecol Oncol.* 2006;100(2):412–416. doi:10.1016/j.ygyno.2005.10.013

Matulonis UA, Herrstedt J, Oza A, et al. Long-term safety and secondary efficacy endpoints in the ENGOTOV16/NOVA phase 3 trial of niraparib in recurrent ovarian cancer. Presented at: Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer; March 19-21, 2021; Virtual. Abstract 37.

McGonigle, K.F., Muntz, H.G., Vuky, J., et al. Combined Weekly Topotecan and Biweekly Bevacizumab in Women With Platinum-Resistant Ovarian, Peritoneal or Fallopian Tube Cancer: Results of a Phase 2 Study. *Cancer.* 2011;117(16):3731-3740. doi:10.1002/cncr.25967

Miller, D.S., Blessing, J.A., Krasner, C.N., et al. Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group. *J Clin Oncol.* 2009;27(16):2686–2691. doi:10.1200/JCO.2008.19.2963

Miller, D.S., Blessing, J.A., Krasner, C.N., et al. Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group. *J Clin Oncol.* 2009;27(16):2686–2691. doi:10.1200/JCO.2008.19.2963

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Mirza, M.R., Åvall Lundqvist, E., Birrer, M.J., et al. Niraparib Plus Bevacizumab Versus Niraparib Alone for Platinum-Sensitive Recurrent Ovarian Cancer (NSGO-AVANOVA2/ENGOT-ov24): A Randomised, Phase 2, Superiority Trial. *Lancet Oncol.* 2019;20(10):1409–1419. doi:10.1016/S1470-2045(19)30515-7

Mirza, M.R., Monk, B., Herrstedt, J., et al. (2016, Dec. 1). Niraparib Maintenance Therapy in Platinum Sensitive, Recurrent Ovarian Cancer: *NEJM*. Retrieved from nejm.org/doi/full/10.1056/NEJMoa1611310

Monk, B.J., Huang, H.Q., Burger, R.A., et al. Patient-Reported Outcomes of a Randomized, Placebo-Controlled Trial of Bevacizumab in the Front-Line Treatment of Ovarian Cancer: A Gynecologic Oncology Group Study. *Gynecol Oncol.* 2013 Mar;128(3):573-8. doi: 10.1016/j.ygyno.2012.11.038. Epub 2012 Dec 4

Moore, K., Colombo, N., Scambia, G., et al. Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer. *NEJM.* 2018; 379: 2495-2505

Moore, K.N., Secord, A.A., Geller, M.A., et al. Niraparib Monotherapy for Late-Line Treatment of Ovarian Cancer (QUADRA): A Multicentre, Open-Label, Single-Arm, Phase 2 Trial [published correction appears in *Lancet Oncol.* 2019 May;20(5):e242]. *Lancet Oncol.* 2019;20(5):636–648. doi:10.1016/S1470-2045(19)30029-4

Moore, K.N., Secord, A.A., Geller, M.A., et al. Niraparib Monotherapy for Late-Line Treatment of Ovarian Cancer (QUADRA): A Multicentre, Open-Label, Single-Arm, Phase 2 Trial [published correction appears in *Lancet Oncol.* 2019 May;20(5):e242]. *Lancet Oncol.* 2019;20(5):636–648. doi:10.1016/S1470-2045(19)30029-4

Mutch, D.G., Orlando, M., Goss, T., et al. Randomized Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer. *J Clin Oncol.* 2007;25(19):2811-2818. doi:10.1200/JCO.2006.09.6735

National Cancer Institute. Cancer Statistics. Retrieved from seer.cancer.gov/statfacts/html/livibd.html

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Accessed Jan 20, 2020

of_trametinib_in_patients_with_recurrent_or_progressive_low-grade_serous_ovarian_or_peritoneal_cancer

Omura, G.A., Brady, M.F., Look, K.Y., et al. Phase III Trial of Paclitaxel at Two Dose Levels, the Higher

Oza, A.M., Cook, A.D., Pfisterer, J., Standard Chemotherapy With or Without Bevacizumab for Women With Newly Diagnosed Ovarian Cancer (ICON7): Overall Survival Results of a Phase 3 Randomised Trial. *Lancet Oncol.* 2015 Aug;16(8):928-36. doi: 10.1016/S1470-2045(15)00086-8. Epub 2015 Jun 23

Ozols, R.F., Bundy, B.N., Greer, B.E., Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: a Gynecologic Oncology Group Study. *J Clin Oncol.* 2003 Sep 1;21(17):3194-200. Epub 2003 Jul 14

Parmar, M.K., Ledermann, J.A., Colombo, N., et al. Paclitaxel Plus Platinum-Based Chemotherapy Versus Conventional Platinum-Based Chemotherapy in Women With Relapsed Ovarian Cancer: The ICON4/AGOVAR-2.2 trial. *Lancet* 361:2099-2106, 2003

Perren, T.J., Swart, A.M., Pfisterer, J., et al. A Phase 3 Trial of Bevacizumab in Ovarian Cancer. *N Engl J Med.* 2011 Dec 29;365(26):2484-96. doi: 10.1056/NEJMoa1103799

Pfisterer, J., Dean, A.P., Baumann, K., et al. Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab (CD-BEV) vs. Carboplatin/Gemcitabine/Bevacizumab (CG-BEV) in Patients With Recurrent Ovarian Cancer: A Prospective Randomized Phase III ENGOT/GCIG-Intergroup study (AGO study group, AGOAustria, ANZGOG, GINECO, SGCTG). *Ann Oncol.* 2018;29 Suppl 8:viii332–viii333. doi:10.1093/annonc/mdy285.142

Pfisterer, J., Plante, M., Vergote, I., et al. Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG and the EORTC GCG. *J Clin Oncol.* 2006;24(29):4699–4707. doi:10.1200/JCO.2006.06.0913

Pignata, S., Lorusso, D., Scambia, G., et al. Pazopanib Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone for Platinum-Resistant or Platinum-Refractory Advanced Ovarian Cancer (MITO 11): A Randomized, Open-Label, Phase 2 Trial. *Lancet Oncol.* 2015;16(5):561-568. doi:10.1016/S1470-2045(15)70115-4

Pignata, S., Scambia, G., Ferrandina, G., et al. Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin as First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial. *J Clin Oncol.* 2011 Sep 20;29(27):3628-35. doi: 10.1200/JCO.2010.33.8566. Epub 2011, Aug. 15

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Pignata, S., Scambia, G., Katsaros, D., et al. Carboplatin Plus Paclitaxel Once a Week Versus Every 3 Weeks in Patients With Advanced Ovarian Cancer (MITO-7): A Randomised, Multicentre, Open-Label, Phase 3 Trial. *Lancet Oncol.* 2014 Apr;15(4):396-405. doi: 10.1016/S1470-2045(14)70049-X. Epub 2014 Feb 28

Pujade-Lauraine, E., Hilpert, F., Weber, B., et al. Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial [published correction appears in *J Clin Oncol.* 2014 Dec 10;32(35):4025]. *J Clin Oncol.* 2014;32(13):1302-1308. doi:10.1200/JCO.2013.51.4489

Pujade-Lauraine, E., Ledermann, J.A., Selle, F., et al. Olaparib Tablets as Maintenance Therapy in Patients With Platinum-Sensitive, Relapsed Ovarian Cancer and a BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial [published correction appears in *Lancet Oncol.* 2017 Sep;18(9):e510]. *Lancet Oncol.* 2017;18(9):1274–1284. doi:10.1016/S1470-2045(17)30469-2

Pujade-Lauraine, E., Wagner, U., Aavall-Lundqvist, E., et al. Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse. *J Clin Oncol.* 2010;28(20):3323–3329. doi:10.1200/JCO.2009.25.7519

Ramirez, P.T., Schmeler, K.M., Milam, M.R., et al. Efficacy of Letrozole in the Treatment of Recurrent Platinum- and Taxane-Resistant High-Grade Cancer of the Ovary or Peritoneum. *Gynecol Oncol.* 2008;110(1):56–59. doi:10.1016/j.ygyno.2008.03.014

Ray-Coquard, I., Pautier, P., Pignata, S., et al. Olaparib Plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. *NEJM.* 2019; 381: 2416-2428

Rose, P.G., Blessing, J.A., Mayer, A.R., et al. Prolonged Oral Etoposide as Second-Line Therapy for Platinum-Resistant and Platinum-Sensitive Ovarian Carcinoma: A Gynecologic Oncology Group Study. *J Clin Oncol.* 1998;16(2):405-410. doi:10.1200/JCO.1998.16.2.405

Rose, P.G., Mossbruger, K., Fusco, N., et al. Gemcitabine Reverses Cisplatin Resistance: Demonstration of Activity in Platinum- and Multidrug-Resistant Ovarian and Peritoneal Carcinoma. *Gynecol Oncol.* 2003;88(1):17–21. doi:10.1006/gyno.2002.6850

Rothenberg, M.L., Liu, P.Y., Wilczynski, S., et al. Phase II Trial of Vinorelbine for Relapsed Ovarian Cancer: A Southwest Oncology Group Study. *Gynecol Oncol.* 2004;95(3):506–512. doi:10.1016/j.ygyno.2004.09.004

Rothenberg, M.L., Liu, P.Y., Wilczynski, S., et al. Phase II Trial of Vinorelbine for Relapsed Ovarian Cancer: A Southwest Oncology Group Study. *Gynecol Oncol.* 2004;95(3):506–512. doi:10.1016/j.ygyno.2004.09.004

Sehouli, J., Chekerov, R., Reinthaller, A., et al. Topotecan Plus Carboplatin Versus Standard Therapy With Paclitaxel Plus Carboplatin (PC) or Gemcitabine Plus Carboplatin (GC) or Pegylated Liposomal Doxorubicin Plus Carboplatin (PLDC): A Randomized Phase III Trial of the NOGGO-AGO-Study GroupAGO Austria and GEICO-ENGOT-GCIG Intergroup Study (HECTOR). *Ann Oncol.* 2016;27(12):2236–2241. doi:10.1093/annonc/mdw418

Sikic BI, Scudder SA, Ballon SC, et al. High-dose megestrol acetate therapy of ovarian carcinoma: a phase II study by the Northern California Oncology Group. *Semin Oncol.* 1986;13(4 Suppl 4):26–32.

Sikic, B.I., Scudder, S.A., Ballon, S.C., et al. High-Dose Megestrol Acetate Therapy of Ovarian Carcinoma: A Phase II Study by the Northern California Oncology Group. *Semin Oncol.* 1986;13(4 Suppl 4):26–32

Smyth, J.F., Gourley, C., Walker, G., et al. Antiestrogen Therapy Is Active in Selected Ovarian Cancer Cases: The Use of Letrozole in Estrogen Receptor-Positive Patients. *Clin Cancer Res.* 2007;13(12):3617–3622. doi:10.1158/1078-0432.CCR-06-2878

Smyth, J.F., Gourley, C., Walker, G., et al. Antiestrogen Therapy Is Active in Selected Ovarian Cancer Cases: The Use of Letrozole in Estrogen Receptor-Positive Patients. *Clin Cancer Res.* 2007;13(12):3617–3622. doi:10.1158/1078-0432.CCR-06-2878

Spellman, et al. Cancer Genome Atlas Research Network. Integrated Genomic Analyses of Ovarian Carcinoma. *Nature* 2011; 474: 609–15

Strauss, H.G., Henze, A., Teichmann, A., et al. Phase II Trial of Docetaxel and Carboplatin in Recurrent Platinum-Sensitive Ovarian, Peritoneal and Tubal Cancer. *Gynecol Oncol.* 2007;104(3):612–616. doi:10.1016/j.ygyno.2006.09.023

Sugiyama, T., Okamoto, A., Enomoto, T., et al. Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial. *J Clin Oncol.* 2016;34(24):2881–2887. doi:10.1200/JCO.2016.66.9010

Swisher, E.M., Lin, K.K., Oza, A.M., et al. Rucaparib in Relapsed, Platinum-Sensitive High-Grade Ovarian Carcinoma (ARIEL2 Part 1): An International, Multicentre, Open-Label, Phase 2 Trial. *Lancet Oncol.* 2017;18(1):75–87. doi:10.1016/S1470-2045(16)30559-9

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Swisher, E.M., Lin, K.K., Oza, A.M., et al. Rucaparib in Relapsed, Platinum-Sensitive High-Grade Ovarian Carcinoma (ARIEL2 Part 1): An International, Multicentre, Open-Label, Phase 2 Trial. *Lancet Oncol.* 2017;18(1):75–87. doi:10.1016/S1470-2045(16)30559-9

Teneriello, M.G., Tseng, P.C., Crozier, M., et al. Phase II Evaluation of Nanoparticle Albumin-Bound Paclitaxel in Platinum-Sensitive Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer. *J Clin Oncol.* 2009;27(9):1426–1431. doi:10.1200/JCO.2008.18.9548

Tewari, K.S., Burger, R.A., Enserro, D., et al. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. *J Clin Oncol.* 2019; 37: 2317-2328

Vasey, P.A., Jayson, G.C., Gordon, A., et al. Phase III Randomized Trial of Docetaxel-Carboplatin Versus Paclitaxel-Carboplatin as First-Line Chemotherapy for Ovarian Carcinoma. *J Natl Cancer Inst.* 2004 Nov 17;96(22):1682-91. PMID: 15547181 DOI: 10.1093/jnci/djh323

Verschraegen, C.F., Sittisomwong, T., Kudelka, A.P., et al. Docetaxel for Patients With Paclitaxel-Resistant Müllerian Carcinoma. *J Clin Oncol.* 2000;18(14):2733-2739. doi:10.1200/JCO.2000.18.14.2733

Von Gruenigen, V.E., Huang, H.Q., Beumer, J.H., et al. Chemotherapy Completion in Elderly Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer – an NRG Oncology/Gynecologic Oncology Group Study. *Gynecol Oncol* 2017; 144(3): 459-467

Wadler, S., Yeap, B., Vogl, S., et al. Randomized Trial of Initial Therapy With Melphalan Versus CisplatinBased Combination Chemotherapy in Patients With Advanced Ovarian Carcinoma: Initial and Long-Term Results – Eastern Cooperative Oncology Group Study E2878. *Cancer.* 1996;77(4):733–742

Wagner, U., Marth, C., Largillier, R., et al. Final Overall Survival Results of Phase III GCIG CALYPSO Trial of Pegylated Liposomal Doxorubicin and Carboplatin vs. Paclitaxel and Carboplatin in Platinum-Sensitive Ovarian Cancer Patients. *Br J Cancer.* 2012;107(4):588–591. doi:10.1038/bjc.2012.307

Walker JL, Brady MF, Wenzel L, et al. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study [published correction appears in *J Clin Oncol.* 2019 Sep 1;37(25):2299]. *J Clin Oncol.* 2019;37(16):1380-1390. doi:10.1200/JCO.18.01568

Walker, J.L., Brady, M.F., Wenzel, L., et al. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study [published correction appears in *J Clin Oncol.* 2019 Sep 1;37(25):2299]. *J Clin Oncol.* 2019;37(16):1380-1390. doi:10.1200/JCO.18.01568

Walker, J.L., Brady, M.F., Wenzel, L., et al. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study [published correction appears in *J Clin Oncol.* 2019 Sep 1;37(25):2299]. *J Clin Oncol.* 2019;37(16):1380-1390. doi:10.1200/JCO.18.01568

Williams, C., Simera, I., Bryant, A., et al. Tamoxifen for Relapse of Ovarian Cancer. *Cochrane Database of Systematic Reviews* 2010, Issue 3. Art. No.: CD001034. DOI: 10.1002/14651858.CD001034.pub2

Wolf, J.K., Bodurka, D.C., Verschraegen, C., et al. A Phase II Trial of Oral Capecitabine in Patients With Platinum – and Taxane – Refractory Ovarian, Fallopian Tube or Peritoneal Cancer. *Gynecol Oncol.* 2006;102(3):468–474. doi:10.1016/j.ygyno.2005.12.040

Wolf, J.K., Bodurka, D.C., Verschraegen, C., et al. A Phase II Trial of Oral Capecitabine in Patients With Platinum – and Taxane – Refractory Ovarian, Fallopian Tube or Peritoneal Cancer. *Gynecol Oncol.* 2006;102(3):468-474. doi:10.1016/j.ygyno.2005.12.040

Wright, A.A., Bohlke, K., Armstrong, D.K., et al. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol.* 2016. 34(28): 3460-3473

Zhang, S., Royer, R., Li, S., et al. Frequencies of BRCA1 and BRCA2 Mutations Among 1,342 Unselected Patients With Invasive Ovarian Cancer. *Gynecol Oncol* 2011; 121: 353–57

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.